Protalix BioTherapeutics, Inc.
PLX
$1.98
$0.021.02%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 292.32% | -325.24% | 156.15% | 142.70% | -42.93% |
| Total Depreciation and Amortization | 14.68% | 12.35% | 10.05% | 8.74% | 7.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 19.70% | -10.53% | -44.92% | 35.66% | 610.82% |
| Change in Net Operating Assets | 37.22% | -1,345.25% | -260.59% | -281.48% | -419.85% |
| Cash from Operations | 2,738.11% | -238.26% | -221.19% | 19.15% | -109.75% |
| Capital Expenditure | -111.41% | -27.77% | -49.95% | 14.86% | 33.96% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -22.54% | -113.24% | -173.46% | 126.79% | 126.77% |
| Cash from Investing | -51.96% | -156.05% | -186.33% | 119.34% | 120.48% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | -- | -- |
| Issuance of Common Stock | -49.44% | 157.20% | -- | -- | -16.59% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 137.55% | 155.53% | 162.71% | -- | -212.32% |
| Foreign Exchange rate Adjustments | -583.33% | -288.00% | 167.86% | 176.19% | 130.38% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 377.94% | -31.13% | -296.57% | 77.79% | -33.02% |